Trimetazidine Normalizes Postischemic Function of Hypertrophied Rat Hearts

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2005-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/JPET.104.082636PMID 15840766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Das Herz bei arterieller Hypertonie

  2006cited by this paper
• Metabolic phenotyping of the diseased rat heart using 13C-substrates and ex vivo perfusion in the working mode

  2004cited by this paper
• Mechanisms for Increased Glycolysis in the Hypertrophied Rat Heart

  2004cited by this paper
• Regular exercise is associated with a protective metabolic phenotype in the rat heart.

  2004cited by this paper
• Transcriptional regulation of energy substrate metabolism in normal and hypertrophied heart

  2003cited by this paper
• Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine

  2003cited by this paper
• Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase

  2003cited by this paper
• The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase

  2003cited by this paper
• Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.

  2002cited by this paper
• Energy Metabolism in the Hypertrophied Heart

  2002cited by this paper
• Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support.

  2002cited by this paper
• High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation.

  2002influential reference
• A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction.

  2001cited by this paper
• Defective Fatty Acid Uptake in the Spontaneously Hypertensive Rat Is a Primary Determinant of Altered Glucose Metabolism, Hyperinsulinemia, and Myocardial Hypertrophy*

  2001cited by this paper
• Accelerated glycolysis and greater postischemic dysfunction in hypertrophied rat hearts are independent of coronary flow.

  2001cited by this paper
• [Fifty years of Framingham Study contributions to understanding hypertension].

  2001cited by this paper
• Effects of cardiogenic shock on lactate and glucose metabolism after heart surgery

  2000cited by this paper
• Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals.

  2000cited by this paper
• The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

  2000cited by this paper
• Dichloroacetate improves postischemic function of hypertrophied rat hearts.

  2000cited by this paper
• Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia.

  2000cited by this paper
• Fifty years of Framingham Study contributions to understanding hypertension

  2000cited by this paper
• Why is left ventricular hypertrophy so predictive of morbidity and mortality?

  1999cited by this paper
• Molecular mechanisms of myocardial remodeling.

  1999cited by this paper
• Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia.

  1999cited by this paper
• Effects of Trimetazidine on Metabolic and Functional Recovery of Postischemic Rat Hearts

  1998cited by this paper
• Metabolic inhibition in the perfused rat heart: evidence for glycolytic requirement for normal sodium homeostasis.

  1998influential reference
• Ionic and metabolic imbalance as potential factors of ischemia reperfusion injury.

  1998cited by this paper
• Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions.

  1997influential reference
• Fatty acid oxidation enzyme gene expression is downregulated in the failing heart.

  1996cited by this paper
• Stunned myocardium after rapid correction of acidosis. Increased oxygen cost of contractility and the role of the Na(+)-H+ exchange system.

  1994cited by this paper
• Plasma fatty acid levels in infants and adults after myocardial ischemia.

  1994cited by this paper
• Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts.

  1994cited by this paper
• Effects of Trimetazidine on Ischemic Contracture in Isolated Perfused Rat Hearts

  1994influential reference
• An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts.

  1993cited by this paper
• Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.

  1993cited by this paper
• The functional recovery of post-ischemic myocardium requires glycolysis during early reperfusion.

  1993influential reference
• The heart in hypertension.

  1992cited by this paper
• Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts.

  1990cited by this paper
• The protective effects of trimetazidine on normothermic ischemic myocardium in rats

  1989cited by this paper
• Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart.

  1987influential reference
• Protons and anaerobiosis.

  1983cited by this paper

• Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial

  2025cites this paper
• Modulation of cardiac fatty acid or glucose oxidation to treat heart failure in preclinical models: a systematic review and meta-analysis

  2025cites this paper
• Cardiac Energy Metabolism in Diabetes: Emerging Therapeutic Targets and Clinical Implications.

  2025cites this paper
• High sugar diet–induced fatty acid oxidation potentiates cytokine-dependent cardiac ECM remodeling

  2024cites this paper
• The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity

  2021cites this paper
• Mitochondrial Dysfunction and Diabetes: Is Mitochondrial Transfer a Friend or Foe?

  2019cites this paper
• The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes

  2019cites this paper
• AMPK: a therapeutic target of heart failure—not only metabolism regulation

  2018cites this paper
• Dioxygen and Metabolism; Dangerous Liaisons in Cardiac Function and Disease

  2017cites this paper
• Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes.

  2016cites this paper
• Benefits of trimetazidine ( TMZ ) in obese patients

  2016cites this paper
• An evaluation of trimetazidine as a therapeutic intervention in a newly established ex vivo mouse model of acute heart failure

  2016cites this paper
• Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.

  2016cites this paper
• Cardiac Energy Metabolic Alterations in Pressure Overload–Induced Left and Right Heart Failure (2013 Grover Conference Series)

  2015cites this paper
• Metabolic efficiency in remodeled failing hearts

  2015cites this paper
• Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy

  2014influential citation
• Dichloroacetate selectively improves cardiac function and metabolism in female and male rainbow trout.

  2014cites this paper
• 1 Dichloroacetate selectively improves cardiac function and metabolism in female and male rainbow 1 trout 2 3

  2014cites this paper
• Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.

  2014cites this paper
• Sex and Gender Differences in Cardiovascular Physiology – Back to the Basics Dichloroacetate selectively improves cardiac function and metabolism in female and male rainbow trout

  2014cites this paper
• Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure.

  2013cites this paper
• Targeting mitochondrial oxidative metabolism as an approach to treat heart failure.

  2013cites this paper
• New pharmacological targets in the treatment of heart failure: inhibition of free fatty oxidation by trimetazidine

  2012cites this paper
• Metabolic Remodelling of the Hypertrophied Heart

  2011cites this paper
• Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.

  2011cites this paper
• Demand-induced ischemia in volume expanded isolated rat heart; the effect of dichloroacetate and trimetazidine.

  2010cites this paper
• Myocardial fatty acid metabolism in health and disease.

  2010cites this paper
• Metabolic remodelling of the failing heart: beneficial or detrimental?

  2009cites this paper
• Impaired energetics in heart failure - a new therapeutic target.

  2008cites this paper
• Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.

  2008cites this paper
• Metabolic remodelling of the failing heart: beneficial or detrimental?

  2008cites this paper
• Metabolic mechanisms in heart failure.

  2007cites this paper
• Partial inhibition of fatty acid β-oxidation with trimetazidine - a novel approach to the treatment of ischemic heart disease

  2007cites this paper
• A Comparison between Ranolazine and CVT-4325, a Novel Inhibitor of Fatty Acid Oxidation, on Cardiac Metabolism and Left Ventricular Function in Rat Isolated Perfused Heart during Ischemia and Reperfusion

  2007cites this paper
• Gender and post-ischemic recovery of hypertrophied rat hearts

  2006influential citation